Abstract Search

ea0084op-07-36 | Oral Session 7: Thyroid Cancer Basic | ETA2022

Loss of tumor cell MHC class ii expression as driver of relapse to dabrafenib and trametinib in mouse BRAF-mutant anaplastic thyroid cancer

Tiedje Vera , Qin Tianyue , Im Soo-Yeon , P Krishnamoorthy Gnana , A. Knauf Jeffrey , A. Fagin James

Objectives: BRAFV600E- anaplastic thyroid cancers (ATCs) show remarkable responses to dabrafenib and trametinib (dab/tram) an effect that may be in part immune-mediated. Murine BRAFV600E-ATCs regress upon BRAF inhibition. We find that recurrences are frequent and associated with loss of Mhc class II (MhcII) expression. Our goal was to investigate the mechanisms of loss of antigen presentation by tumor cells and whether this contributes to disease recurren...

0 shares

ea0041oc14.5 | Thyroid Cancer | ECE2016

Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma in Germany: a retrospective multi-center study

Wendler Julia , Kroiss Matthias , Gast Katja , Kreissl Michael , Allelein Stephanie , Lichtenauer Urs , Blaser Rainer , Kuhn Klaus , Spitzweg Christine , Fassnacht Martin , Fuhrer Dagmar , Schott Matthias , Tiedje Vera

Context: Anaplastic (ATC) thyroid carcinoma is an orphan disease accounting for about 2% of all malignant thyroid tumors. ATC confers a dismal prognosis and standard treatment is not established.Objective: To describe the epidemiology, current treatment regimens and outcome of ATC, to identify clinical prognostic markers and treatment factors associated with improved prognosis. To establish a consensus treatment schedule.Design: Re...

0 shares

Endocrine Abstracts

Loss of tumor cell MHC class ii expression as driver of relapse to dabrafenib and trametinib in mouse BRAF-mutant anaplastic thyroid cancer

Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma in Germany: a retrospective multi-center study

BiosciAbstracts